Gene · 27329
Papers2,231
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
281 to 300 of 2,231
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Inhibition of the ANGPTL3/8 Complex for the Prevention and Treatment of Atherosclerotic Cardiovascular Disease. | Curr Atheroscler Rep | 2024 | 39565562 | PubTator, text mining | PubMed |
| Correction: Circulating levels of PCSK9, ANGPTL3 and lp(a) in stage III breast cancers. | BMC Cancer | 2024 | 39548406 | PubTator, text mining | PubMed |
| Simultaneously blocking ANGPTL3 and CD47 prevents the progression of atherosclerosis through regulating lipid metabolism, macrophagic efferocytosis and lipid peroxidation. | Pharmacol Res | 2024 | 39488258 | PubTator, text mining | PubMed |
| ANGPTL3 as a target for treating lipid disorders in type 2 diabetes patients. | Lipids Health Dis | 2024 | 39487451 | PubTator, text mining | PubMed |
| Adding a New Piece to the ASGR1 Puzzle: ANGPTL3. | Arterioscler Thromb Vasc Biol | 2024 | 39479768 | PubTator, text mining | PubMed |
| Messenger interference RNA therapies targeting apolipoprotein C-III and angiopoietin-like protein 3 for mixed hyperlipidemia: the future of plozasiran and zodasiran. | Expert Rev Clin Pharmacol | 2024 | 39469883 | PubTator, text mining | PubMed |
| Inflammatory and Lipid Biomarkers in Early Atherosclerosis: A Comprehensive Analysis. | Life (Basel) | 2024 | 39459610 | PubTator, text mining | PubMed |
| Identification of potential novel targets for treating inflammatory bowel disease using Mendelian randomization analysis. | Int J Colorectal Dis | 2024 | 39414629 | PubTator, text mining | PubMed |
| Common pitfalls in drug target Mendelian randomization and how to avoid them. | BMC Med | 2024 | 39407214 | PubTator, text mining | PubMed |
| ASGR1 Deficiency Inhibits Atherosclerosis in Western Diet-Fed ApoE-/- Mice by Regulating Lipoprotein Metabolism and Promoting Cholesterol Efflux. | Arterioscler Thromb Vasc Biol | 2024 | 39387120 | PubTator, text mining | PubMed |
| Joint testing of rare variant burden scores using non-negative least squares. | Am J Hum Genet | 2024 | 39366334 | PubTator, text mining | PubMed |
| Effect of Cholesterol-Lowering Variants in ANGPTL3 and APOB Genes on Liver Disease. | J Am Coll Cardiol | 2024 | 39365223 | PubTator, text mining | PubMed |
| Beyond the Guidelines: Perspectives on Management of Pediatric Patients with Hypertriglyceridemia. | Curr Atheroscler Rep | 2024 | 39347913 | PubTator, text mining | PubMed |
| Yield of genetic association signals from genomes, exomes and imputation in the UK Biobank. | Nat Genet | 2024 | 39322778 | PubTator, text mining | PubMed |
| Glutamine metabolism-related genes predict the prognostic risk of acute myeloid leukemia and stratify patients by subtype analysis. | Hereditas | 2024 | 39300580 | PubTator, text mining | PubMed |
| Angiopoietin-like Proteins and Lipoprotein Lipase: The Waltz Partners That Govern Triglyceride-Rich Lipoprotein Metabolism? Impact on Atherogenesis, Dietary Interventions, and Emerging Therapies. | J Clin Med | 2024 | 39274442 | PubTator, text mining | PubMed |
| Liver-targeted Angptl4 silencing by antisense oligonucleotide treatment attenuates hyperlipidaemia and atherosclerosis development in APOE*3-Leiden.CETP mice. | Cardiovasc Res | 2024 | 39259836 | PubTator, text mining | PubMed |
| Simultaneously blocking ANGPTL3 and IL-1β for the treatment of atherosclerosis through lipid-lowering and anti-inflammation. | Inflamm Res | 2024 | 39254873 | PubTator, text mining | PubMed |
| Therapeutic Gene Editing in Dyslipidemias. | Rev Cardiovasc Med | 2024 | 39228490 | PubTator, text mining | PubMed |
| Postprandial exercise regulates tissue-specific triglyceride uptake through angiopoietin-like proteins. | JCI Insight | 2024 | 39171527 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/27329/papers?page=15